What is InteRNA Technologies?
InteRNA Technologies operates at the intersection of molecular biology and clinical oncology, specializing in the development of microRNA-based therapeutics. The company's core mission involves targeting the fundamental processes that drive human disease, with a primary focus on oncology. By utilizing proprietary technology to modulate miRNA expression, InteRNA aims to provide novel treatment modalities for patients with limited therapeutic options. Their market position is defined by a rigorous scientific approach to drug development, supported by a portfolio of intellectual property that addresses the complex mechanisms of cancer initiation and progression.
How much funding has InteRNA Technologies raised?
InteRNA Technologies has raised a total of $32.9M across 2 funding rounds:
Series A
$10.5M
Series B
$22.4M
Series A (2015): $10.5M with participation from INKEF Capital and Aglaia Biomedical Ventures B.V.
Series B (2021): $22.4M led by Oost NL, AurorA Science, waterman-ventures.com, and Aglaia Oncology Funds
Key Investors in InteRNA Technologies
INKEF Capital
An Amsterdam-based venture capital firm backed by the Dutch pension fund ABP, focusing on long-term support for innovative companies in healthcare and technology.
Aglaia Biomedical Ventures B.V.
An oncology-focused specialist investor that matures early-stage breakthrough inventions to transform cancer prevention, diagnosis, and therapy.
Oost NL
A regional development agency for the East Netherlands that invests in innovative companies to stimulate regional economic growth and technological advancement.
What's next for InteRNA Technologies?
Looking ahead, the infusion of capital will likely be directed toward expanding the company's clinical trial infrastructure and enhancing its R&D capabilities. As InteRNA Technologies moves deeper into the clinical-stage, the focus will shift toward de-risking its lead assets and preparing for potential licensing agreements or strategic partnerships with larger pharmaceutical entities. The company's ability to maintain its momentum will depend on the successful execution of its current clinical roadmap and the continued validation of its miRNA platform in human trials. Keywords: InteRNA Technologies, microRNA therapeutics, oncology biotech, clinical-stage development, venture capital, drug discovery, cancer research, biotech investment.
See full InteRNA Technologies company page
